Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹Uls Gaia Espinho, Vila Nova de Gaia, Portugal
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05552976
- Locations
- 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸TOI Clinical Research, Cerritos, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 75
- Registration Number
- NCT05497804
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05495620
A Study of Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Barnes-jewish Hospital, Saint Louis, Missouri, United States
🇧🇪ZNA Stuivenberg, Antwerpen, Belgium
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 80
- Registration Number
- NCT05434689
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 66
- Registration Number
- NCT05199311
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05060627
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.